Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker Testing - Episode 8

Overcoming Barriers to NSCLC Biomarker Testing

,

Key opinion leaders delve into the challenges posed by payers, costs, out-of-pocket maximums, and the need for letters of medical necessity, while also addressing additional sources of resistance encountered in clinical practice.

EP. 1: Optimizing NSCLC Patient Outcomes Through Concurrent Biomarker Testing
EP. 2: Concurrent NSCLC Biomarker Testing at Diagnosis
EP. 3: NCCN Guidelines: Optimizing NSCLC Treatment with Concurrent Biomarker Testing
EP. 4: Improving Time-to-Treatment for Patients With Non-Small Cell Lung Cancer
EP. 5: Biomarker Testing in Early-Stage NSCLC
EP. 6: Reflex Testing for Patients with Suspected Lung Cancer
EP. 7: Challenges of NSCLC Biomarker Testing in Clinical Practice
Now Viewing
EP. 8: Overcoming Barriers to NSCLC Biomarker Testing
EP. 9: Key Takeaways for Concurrent Biomarker Testing in NSCLC

Related Content:

Optimizing Treatment Outcomes in Advanced NSCLC with Concurrent Biomarker TestingThe US Oncology NetworkLung CancerOncLive News Network®
Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC
Defining Resectability in Stage III NSCLC: Addressing Key Controversies
FDA Grants Priority Review to Taletrectinib in ROS1+ Advanced NSCLC